78D Stock Overview
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer’s disease in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Alzinova AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.13 |
| 52 Week High | kr0.30 |
| 52 Week Low | kr0.12 |
| Beta | 0.99 |
| 1 Month Change | -9.17% |
| 3 Month Change | -37.93% |
| 1 Year Change | -38.67% |
| 3 Year Change | -81.25% |
| 5 Year Change | n/a |
| Change since IPO | -80.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78D | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -0.2% | 0.5% |
| 1Y | -38.7% | -22.8% | 1.3% |
Return vs Industry: 78D underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 78D underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 78D volatility | |
|---|---|
| 78D Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 78D's share price has been volatile over the past 3 months.
Volatility Over Time: 78D's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 4 | Kristina Torfgard | www.alzinova.com |
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer’s disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer’s disease; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Alzinova AB (publ) Fundamentals Summary
| 78D fundamental statistics | |
|---|---|
| Market cap | €6.48m |
| Earnings (TTM) | -€1.41m |
| Revenue (TTM) | €1.70m |
3.8x
P/S Ratio-4.6x
P/E RatioIs 78D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78D income statement (TTM) | |
|---|---|
| Revenue | kr19.87m |
| Cost of Revenue | kr0 |
| Gross Profit | kr19.87m |
| Other Expenses | kr36.35m |
| Earnings | -kr16.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 100.00% |
| Net Profit Margin | -82.92% |
| Debt/Equity Ratio | 0.7% |
How did 78D perform over the long term?
See historical performance and comparison